

To update the respective Indian addresses/e-mail addresses/phone or mobile numbers in the records maintained by the Registrar or by our Company, in case shares held in physical mode or contact with their Depository Participant in case shares held in demat mode, Eligible Equity Shareholders should visit <https://rights.alankit.com/>.

Eligible Equity Shareholders can also obtain the details of their respective Rights or Entitlements from the website of the Registrar to the Issue's website at <https://rights.alankit.com/> by entering their DP-ID and Client-ID or Folio Number (for Eligible Equity Shareholders holding Equity Shares in physical form as on Record date), and PAN. The link for the same shall also be available on the website of our Company at www.ia.ooo.

Further, our Company will undertake all adequate steps to reach out to the Eligible Equity Shareholders who have provided their Indian address through other means, as may be feasible.

OTHER IMPORTANT LINKS AND HELPLINE

The Shareholders can visit following links for the below-mentioned purposes:

- a. Frequently asked questions and online/ electronic dedicated investor helpdesk for guidance on the Application process and resolution of difficulties faced by the Investors: <https://rights.alankit.com/>;
- b. Updation of Indian address/ e-mail address/ mobile number in the records maintained by the Registrar to the Issue or our Company <https://rights.alankit.com/>;
- c. Updation of demat account details by Eligible Equity Shareholders holding shares in physical form: <https://rights.alankit.com/>;
- d. Submission of self-attested PAN, client master sheet and demat account details by non-resident Eligible Shareholders infibeamrights@alankit.com;

Investors may contact the Registrar or our Company Secretary and Compliance Officer for any pre-Issue or post-Issue related matter. All grievances relating to the ASBA process, with a copy to the SEBI and the Registrar, giving full details such as name, address of the Applicant, contact number(s), E-mail address of the SCSBs (in case of ASBA process), account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA Account number and the Designated Branch of the SCSBs where the Application Form or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process). For details on the ASBA process, see "Terms of the Issue" on page 85.

BANKER TO THE ISSUE AND REFUND BANK: Axis Bank Limited

MONITORING AGENCY: CARE Ratings Limited


FOR THE RISK FACTOR AND OTHER DETAILS, KINDLY REFER TO THE LETTER OF OFFER.

COMPANY DETAILS



INFIBEAM AVENUES LIMITED
CIN: L64203GJ2010PLC061366
Registered Office: 28th Floor, GIFT Two Building, Block No. 56, Road-5C, Zone-5, GIFT CITY, Gandhinagar, Gujarat India - 382050.
Contact No: +91 7967772204
Contact Person: Mr. Shyamal Trivedi, Sr. Vice President, Company Secretary and Compliance Officer
Email: ir@ia.ooo
Website: www.ia.ooo

REGISTRAR TO THE ISSUE



ALANKIT ASSIGNMENTS LIMITED
CIN: U74210DL1991PLC042569
Address: Alankit House, 4E/2, Jhandewalan Extension, New Delhi-110055
Tel No: +91-011-42541966/952
Email: infibeamrights@alankit.com
Website: <https://rights.alankit.com/>
Contact Person: Mr. Jagdeep Kumar Singla
Investor Grievance Email: infibeamrights@alankit.com
SEBI Registration Number: INR000002532

For Infibeam Avenues Limited
Sd/-
Shyamal Trivedi
Sr. Vice President, Company Secretary & Compliance Officer

Date: June 30, 2025
Place: Gandhinagar

Disclaimer: Our Company is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to issue Equity Shares on a rights basis and has filed a Letter of Offer with the SEBI, BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"). The Letter of Offer is available on the website of SEBI at www.sebi.gov.in, BSE at www.bseindia.com, NSE at www.nseindia.com, SEBI and Registrar to the Issue at <https://rights.alankit.com/>. Investors should note that investment in equity shares involve a high degree of risk and are requested to refer to the Letter of Offer including the section "Risk Factors" beginning on page 25 of the Letter of Offer. Potential investors should not rely on the Letter of Offer for any investment decision.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of Rights Equity Shares for sale in any jurisdiction, including the United States, and any Rights Equity Shares described in this announcement may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. There will be no public offering of Rights Equity Shares in the United States.

This is a public announcement for information purpose only and is not a prospectus announcement and does not constitute an invitation or offer to acquire purchase or subscribe to securities. Not for release, publication or distribution directly or indirectly, outside India.

PUBLIC ANNOUNCEMENT



(Please scan the QR to view the Draft Prospectus)



PHYTO PACK

PHYTOCHEM REMEDIES (INDIA) LIMITED

Our Company was originally incorporated and registered as a private limited Company under Companies Act, 1956 under the name and style of "Phytochem Remedies (India) Private Limited" vide Certificate of Incorporation dated November 27, 2002 bearing registration number 017943 and bearing Corporate Identity Number U24233RJ2002PTC017943, issued by the Registrar of Companies. Further, pursuant to a resolution passed by our Board at a board meeting held on April 07, 2025 and a special resolution passed by our shareholders at an extra-ordinary general meeting held on April 10, 2025, our Company was converted into a public limited company. Consequently, the name of our Company was changed to "Phytochem Remedies (India) Limited" and a fresh Certificate of Incorporation dated April 23, 2025 bearing Corporate Identity Number U17014RJ2002PLC017943 was issued by Registrar of Companies, Central Processing Centre. For details of change in name and registered office of our Company, please refer to chapter titled "History and Certain Corporate Matters" beginning on page 188 of the Draft Prospectus ("Draft Prospectus").

Registered Office: 220, Ashok Nagar Main Road, Udaipur City, Udaipur, Girwa, Rajasthan, India, 313001

Tel: +91 294 4577549 ; **Contact Person:** Namrata Paliwal, Company Secretary and Compliance Officer

E-mail: cs@phytochem.co.in; **Website:** www.phytochem.co.in **Corporate Identity Number:** U17014RJ2002PLC017943

PROMOTERS OF OUR COMPANY ARE ADITI BOHRA, BOHRA AGRIFILMS PRIVATE LIMITED, NIRANJAN SURANA AND SHILPA SURANA

INITIAL PUBLIC OFFER OF UP TO 39,000,000⁽¹⁾ EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF PHYTOCHEM REMEDIES (INDIA) LIMITED (OUR "COMPANY") FOR CASH AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE), AGGREGATING UP TO ₹ [•] LAKHS ("PUBLIC OFFER") OUT OF WHICH [•] EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE FOR CASH, UP TO 1,95,000 EQUITY SHARES AGGREGATING TO ₹ [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE ("MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [•] EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹ [•] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ [•] LAKHS IS HEREAFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE [•] % AND [•] % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" ON PAGE 315 OF THE DRAFT PROSPECTUS.

⁽¹⁾Our Company, in consultation with the LM, may consider issue of specified securities, as may be permitted under applicable law to any person(s) prior to filing of the Prospectus with the RoC ("Pre-IPO Placement"). The Pre-IPO Placement, if undertaken, will be at a price to be decided by our Company, in consultation with the LM. If the Pre-IPO Placement is completed, the amount raised pursuant to the Pre-IPO Placement will be reduced from the Issue, subject to compliance with rule 19(2)(b) of the SCRR. The Pre-IPO Placement, if undertaken, shall not exceed 20% of the size of the Issue. The utilization of the proceeds raised pursuant to the Pre-IPO Placement will be done towards the objects in compliance with applicable law. Prior to the completion of the Issue and the allotment pursuant to the Pre-IPO Placement, our Company shall appropriately intimate the subscribers to the Pre-IPO Placement that there is no guarantee that our Company may proceed with the Issue or the Issue may be successful and will result into listing of the Equity Shares on the Stock Exchange. Further, relevant disclosures in relation to such intimation to the subscribers to the Pre-IPO Placement (if undertaken) shall be appropriately made in the relevant sections of the Prospectus.

This is to inform that the Company has filed the Draft Prospectus dated June 27, 2025, with the SME platform of BSE Limited, in respect of the proposed IPO of the Company in accordance with Chapter IX of the SEBI ICDR Regulations, 2018 (IPO of Small and Medium Enterprises). The Draft Prospectus was filed on June 27, 2025.

This public announcement is made in compliance with the Regulation 247(2) of the SEBI ICDR Regulations, 2018, which requires the draft Issue document shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the exchange, the Issuer and the Lead Manager (LM). Accordingly, it may be noted that the Draft Prospectus, filed by the Company on June 27, 2025 with BSE, is hosted on the website of the BSE at www.bsesme.com and the website of the Company at www.phytochem.co.in, and at the website of LM i.e. Mefcom Capital Markets Limited at www.mefcomcap.in. Our Company hereby invites the members of the public to give their comments to Stock Exchange, to our Company Secretary and Compliance Officer of our Company and/or the LM at their respective addresses mentioned below. All comments must be received by BSE SME and/or our Company and/or LM in relation to the issue on or before 5 p.m. on the 21st day from the aforesaid date of filing the Draft Prospectus with SME Platform of BSE Limited (BSE SME).

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares have not been recommended or approved by the SEBI or Stock Exchange, nor does SEBI or Stock Exchanges guarantee the accuracy or adequacy of the contents of the Draft Prospectus. Specific attention of the investors is invited to the section titled "Risk Factors" beginning on page 29 of the Draft Prospectus.

Any decision to invest in the Equity Shares described in the Draft Prospectus may only be taken after the Prospectus has been filed with the RoC and must be made solely on the basis of such Prospectus as there may be material changes in the Prospectus from the Draft Prospectus. The Equity Shares, when offered through the Prospectus, are proposed to be listed on the SME Platform of BSE SME.

For details of the main objects of the Company as contained in its Memorandum of Association, please refer to the section titled "History and Certain Corporate Matters" beginning on page 188 of the Draft Prospectus. For details of the share capital and capital structure of the Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them, please refer to the section titled "Capital Structure" beginning on page 81 of the Draft Prospectus.

LEAD MANAGER TO THE ISSUE



Mefcom Capital Markets Limited
 5th Floor, 77, Sanchi Building,
 Nehru Place, New Delhi - 110019
Tel: +91 11 4650 0500
E-mail: pri.ipo@mefcomcap.in
Website: www.mefcomcap.in
Investor grievance:
investor.grievance@mefcom.in
SEBI Registration Number: INM000000016
Contact Person: Sushant Sonawane

REGISTRAR TO THE ISSUE



Bigshare Services Private Limited
 S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves
 Road, next to Ahura Centre, Andheri East, Mumbai- 400093,
 Maharashtra, India
Tel: +91 22 6263 8200
E-mail: ipo@bigshareonline.com
Website: www.bigshareonline.com
Investor Grievance ID:
investor@bigshareonline.com
SEBI Registration Number: INR000001385
Contact Person: Vinayak Morbale

Investors can contact our Company Secretary and Compliance Officer, Lead Manager or Registrar to the Issue, in case of any pre issue or post issue related problems, such as non-receipt of letter of allotment, non-credit of allotted Equity shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Prospectus.

For PHYTOCHEM REMEDIES (INDIA) LIMITED

On behalf of the Board of Directors

Sd/

Date : June 28, 2025

Namrata Paliwal

Place : Udaipur

Company Secretary and Compliance Officer

PHYTOCHEM REMEDIES (INDIA) LIMITED is proposing, subject to, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the Draft Prospectus with the Stock Exchange, on June 27, 2025. The Draft Prospectus shall be available on the website of the SME platform of BSE i.e. www.bsesme.com - where equity shares are proposed to be listed, on the website of the Company i.e. www.phytochem.co.in and the website of the LM i.e. Mefcom Capital Markets Limited i.e. www.mefcomcap.in. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" on page 29 of the Draft Prospectus. Potential investors should not rely on the Draft Prospectus for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in "offshore transactions" as defined in, and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made.

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



KASLIWAL PROJECTS LIMITED

CIN: U45400MH2008PLC179623

Our Company was incorporated as 'Kasliwal Projects Private Limited', a private limited company, under the Companies Act, 1956 pursuant to a certificate of incorporation dated March 03, 2008, issued by the Registrar of Companies, Mumbai, Maharashtra (ROC). Subsequently our Company was converted into a public limited company pursuant to a special resolution passed by our shareholders in the extra ordinary general meeting held on August 5, 2024, and the name of our Company was changed to 'Kasliwal Projects Limited' and a fresh Certificate of Incorporation dated October 28, 2024, was issued to our Company by the Registrar of Companies, Central Processing Centre ("ROC"). For further details on the changes in the name and registered office of our Company, see "History and Certain Corporate Matters" on page 222 of this Draft Red Herring Prospectus.

Registered Office: A 1024-1025, Corporate Avenue CHS. Ltd, Near Udyog Bhavan, Sonawala Road, Goregaon East, Mumbai, Maharashtra, India, 400063
Contact Person: Hiren Rajendra Mehta, Company Secretary and Compliance Officer
Telephone: +917021704870 **E-mail:** compliance@kasliwalprojects.com **Website:** <https://kasliwalprojects.com/>

OUR PROMOTERS: MR. PADAM KUMAR JAIN, MR. ANISH PADAM JAIN AND MR. NITISH PADAM JAIN

"THE OFFER IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI (ICDR) REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME")."

THE OFFER

INITIAL PUBLIC OFFER OF UP TO 1,38,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 2.00 EACH OF KASLIWAL PROJECTS LIMITED ("OUR COMPANY") OR THE "ISSUER" FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE (THE "OFFER PRICE") AGGREGATING TO ₹ [•] LAKHS ("THE OFFER"), COMPRISING A FRESH ISSUE OF UP TO 1,11,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 2.00 EACH AGGREGATING UP TO ₹ [•] LAKHS BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 27,00,000 EQUITY SHARES ("OFFERED SHARES") OF FACE VALUE OF ₹ 2.00 EACH AGGREGATING UP TO ₹ [•] LAKHS BY MR. ANISH PADAM JAIN AND MR. NITISH PADAM JAIN ("SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, "OFFER FOR SALE"). OUT OF THE ISSUE UP TO [•] EQUITY SHARES AGGREGATING TO ₹ [•] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE OFFER (THE "MARKET MAKER RESERVATION PORTION"). THE OFFER LESS THE MARKET MAKER RESERVATION PORTION I.E. NET OFFER OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 2.00 EACH AT A PRICE OF ₹ [•] PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE AGGREGATING TO ₹ [•] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER WILL CONSTITUTE [•] % AND [•] %, RESPECTIVELY, OF THE POST OFFER PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 2 EACH AND THE OFFER PRICE IS [•] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF [•] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [•] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND MUMBAI EDITION OF [•] (A WIDELY CIRCULATED MARATHI DAILY NEWSPAPER, MARATHI BEING THE REGIONAL LANGUAGE OF MAHARASHTRA WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE, AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE", THE "STOCK EXCHANGE") FOR UPLOADING ON THEIR WEBSITES IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE "SEBI ICDR REGULATIONS").

In case of any revision in the Working Days, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, in consultation with the BRLM, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchange, by issuing a press release, and also by indicating the change on the respective website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

This offer is being made through the Book Building Process, in terms of Regulation 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 (1) and 253 (2) of the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company and the selling shareholders in consultation with the BRLM may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from a domestic Mutual Fund at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. In the event of undersubscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, the SEBI ICDR Regulations read with SEBI ICDR (Amendment) Regulations, 2025, states that not less than 35% of the Net Offer shall be available for allocation to Individual Investors who applies for minimum application size. Not less than 15% of the Net Offer shall be available for allocation to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹ 10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other sub-category of Non-Institutional Portion. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non-Institutional Investor shall not be less than the minimum application size in Non-Institutional category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule III of the SEBI ICDR (Amendment) Regulations, 2025. All Potential Bidders, other than Anchor Investors, are required to participate in the Offer by mandatorily utilising the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, please refer to the chapter titled "Offer Procedure" on page 388 of this Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations to inform the public that the Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offering of its Equity Shares of face value ₹ 2.00 each pursuant to the Offer and the Draft Red Herring Prospectus dated June 26, 2025 and has been filed with SME Platform of BSE Limited ("BSE SME") on June 27, 2025. The Draft Red Herring Prospectus filed with BSE SME shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of BSE SME at www.bsesme.com on the website of the BRLM at www.corpwis.com and also on the website of the Company <https://kasliwalprojects.com/>. The Company invites public to give comments on the Draft Red Herring Prospectus filed with BSE SME with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of the Company and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or the Company Secretary & Compliance Officer of our Company, and/or to the BRLM in relation to the offer on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with BSE SME.

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the offer unless they can afford to take the risk of losing their investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the offer, including the risks involved. The equity shares in the offer have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the investor is invited to "Risk Factors" on page 31 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the Registrar of Companies (ROC) and must be made solely on the basis of such Draft Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE Limited ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of the Company, see "Capital Structure" beginning on page 78 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "History and Certain Corporate matters" beginning on page 222 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE OFFER	COMPANY SECRETARY & COMPLIANCE OFFICER
 CORPWIS ADVISORS PRIVATE LIMITED CIN: U74900MH2014PTC322723 Address: G-07, Ground Floor, The Summit Business Park (Omikar), Andheri - Kurla Road, Andheri East, Behind Guru Nanak Petrol Pump, Mumbai - 400093, Maharashtra, India. Tel. No.: +91 22 4972 9990 Email: ipo.kasliwal@corpwis.com Website: www.corpwis.com Investor Grievance Email ID: investors@corpwis.com Contact Person: Ms. Shilpa Kanodia SEBI Registration. No.: INM000012962	 PURVA SHAREREGISTRY (INDIA) PRIVATE LIMITED CIN: U67120MH1993PTC074079 Address: 9 Shiv Shakti Industrial Estate, J.R. Boricha Marg, Near Lodha Excelus, Lower Parel East, Mumbai - 400 011, Maharashtra, India Tel No.: 022 4961 4132 / 3522 0056 E-mail: newissue@purvashare.com Website: www.purvashare.com Investor Grievance Email ID: newissue@purvashare.com Contact Person: Ms. Deepali Dhuri SEBI Regn. No.: INR000001112	 Name: Hiren Rajendra Mehta Company Secretary & Compliance Officer KASLIWAL PROJECTS LIMITED Address: A 1024-1025, Corporate Avenue CHS. Ltd, Near Udyog Bhavan, Sonawala Road, Goregaon East, Mumbai, Maharashtra, India, 400063 Telephone: +91 7021704870 Email: compliance@kasliwalprojects.com Website: https://kasliwalprojects.com/ Investors can contact our Company Secretary and Compliance Officer, Book Running Lead Manager or Registrar to the offer, in case of any pre-offer or post-offer related problems, such as non-receipt of letter of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-credit of refund orders and non-receipt of funds by electronic mode etc..

All capitalized terms used and not specifically defined shall have the same meaning as ascribed to them in the Draft Prospectus.

For and on behalf of the Board of Directors

Kasliwal Projects Limited

Sd/-

Hiren Rajendra Mehta

Company Secretary & Compliance Officer

Place: Mumbai, Maharashtra
Date: June 30, 2025

Disclaimer: Kasliwal Projects Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an "initial public offer" of its Equity Shares and has filed the Draft Red Herring Prospectus on June 27, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at www.bsesme.com and is available on the websites of the BRLM at www.corpwis.com and also on the website of the Company <https://kasliwalprojects.com/>. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 31 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.